| Project/Area Number |
15K08036
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Hyogo University of Health Sciences |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
辻川 和丈 大阪大学, 薬学研究科, 教授 (10207376)
田中 明人 兵庫医療大学, 薬学部, 教授 (30454789)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | PCA-1 / ALKBH3 / 抗がん剤 / 前立腺がん / Docetaxel / 併用効果 / 悪性中皮腫 / MESO-4 / ＰＣＡ－１ / ＡＬＫＢＨ３ / 前立腺癌 / 中皮腫 / Cisplatin / 前立腺 |
|---|
| Outline of Final Research Achievements |
We previously developed a novel PCA-1 inhibitor, named HUHS015. We examine anti-cancer effects of HUHS015 in combination with known anti-cancer drugs in our continuous studies. In this study, hormone-independent prostate cancers and malignant mesothelioma were used. We found synagistic effects of HUHS015 in vitro in combination with Docetaxel and Cisplatin, which were often clinically used for hormone-independent prostate cancers treatment. We also found that combinational treatment of HUHS015 with Cisplatin, Irinotecan, Doxorubicin, Vinorelbine and Gemcitabine in malignant mesothelioma synergistically inhibited growth of malignant mesothelioma cells in vitro. Furthermore, additive effects of HUHS015 comibinatorial uses with Docetaxel in vivo were demonstrated, that is, administration of 1 and 2.5 mg/kg of Docetaxel with 32 mg/kg of HUHS015 were more potent than that of only Docetaxel administrations.
|
